BioMerieux (EPA:BIM) shares rose 0.7% on Monday after the diagnostics firm disclosed a regulatory filing intended to broaden access to its vaginitis testing panel in the United States.
The company submitted a combined 510(k) and CLIA waiver application for the BIOFIRE SPOTFIRE Vaginitis Panel, a diagnostic assay designed to produce eight distinct results from a single swab. The panel is configured to detect bacterial vaginosis, yeast and parasite pathogens, and is marketed with a reported turnaround time of 20 minutes.
In parallel with the U.S. filing, BioMerieux plans to submit the SPOTFIRE Vaginitis Panel for CE marking in the European Union as a Class C near-patient test under the In Vitro Diagnostic Regulation, known as IVDR. The firm has indicated an intention to pursue regulatory approvals across both jurisdictions.
Market commentary on the filing timeline came from Morgan Stanley, which noted that the company’s submission schedule appears consistent with previously stated guidance. The brokerage group added that it would expect FDA clearance to occur in the Q4'26/Q1/27 period.
The filings cover two distinct regulatory pathways in the U.S. The 510(k) route is a premarket notification process and the CLIA waiver application seeks authorization that would permit use in settings with waived clinical laboratory status. The company’s dual approach aims to address both market access and operational settings for the test.
Investors reacted modestly to the announcement, with shares edging higher on the day. The filings and the stated timeline set a regulatory milestone for the SPOTFIRE Vaginitis Panel, while the planned CE marking submission signals parallel regulatory work in the EU.
As presented by the company, the SPOTFIRE Vaginitis Panel is designed to consolidate multiple pathogen detections into a single, rapid assay with a 20-minute turnaround and eight reported results from one specimen. The company has initiated formal steps with regulators in the U.S. and is preparing a CE marking submission under IVDR for a Class C near-patient designation in Europe.